In our series, the value of CA IX as a predictive marker of response to doxorubicin appears to be independent of HER2 and/or TOP2A amplification, suggesting a novel mechanism of anthracycline treatment resistance related to tumour hypoxia. The gene discussed is TOP2A; the disease is neoplasm.